In the webinar he stated that the immuntherapies division is very valuable for Admedus, so very unlikely they will divest it, that he is expecting an announcement in this regard (possibly funding) to keep the project going as he stated many times now that it is beyond Admedus financial means to fund any further research.
Ann: Investor Webinar Presentation, page-56
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.20 |
Change
-0.550(3.10%) |
Mkt cap ! $330.6M | |||
| Open | High | Low | Value | Volume |
| $17.75 | $17.75 | $16.88 | $199.1K | 11.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |